NIKKEI 225
38,755.87 +519.80 (+1.36%) HANG SENG
18,420.38 -157.92 (-0.85%) CRUDE OIL
78.73 +0.25 (+0.32%) GOLD FUTURES
2,332.00 +0.80 (+0.03%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,464.92 -473.80 (-0.93%)
Annovis Bio, Inc. (ANVS)
After hours:
| Previous close | 5.18 |
| Open | 5.30 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 800 |
| Day's range | 5.21 - 5.76 |
| 52-week range | 4.86 - 22.49 |
| Volume | |
| Avg. volume | 459,921 |
| Market cap | 59.406M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.48 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.25 |
GlobeNewswireAnnovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps. Dear Friends, The last few days have been very difficult. I received a lot of emails and phone ca
ZacksBlueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
ZacksZoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
